Medscape is available in 5 Language Editions – Choose your Edition here.


Hemolytic Disease of Newborn

  • Author: Sameer Wagle, MBBS, MD; Chief Editor: Ted Rosenkrantz, MD  more...
Updated: Jan 02, 2016


A French midwife was the first to report hemolytic disease of the newborn (HDN) in a set of twins in 1609. In 1932, Diamond and colleagues described the relationship among fetal hydrops, jaundice, anemia, and erythroblasts in the circulation, a condition later called erythroblastosis fetalis. Levine later determined the cause after Landsteiner and Weiner discovered the Rh blood group system in 1940. In 1953, Chown subsequently confirmed the pathogenesis of Rh alloimmunization to be the result of passage of Rh-positive fetal RBCs after transplacental hemorrhage into maternal circulation that lacked this antigen.

In 1966, 2 groups from the United Kingdom and the United States demonstrated, in a combined study, that anti-D immunoglobulin G (IgG) prophylaxis soon after delivery prevented sensitization in Rh-negative women. The World Health Organization (WHO) technical report in 1971 recommended that a dose of 25 mcg (125 IU) of anti-D immunoglobulin G (IgG) should be given intramuscularly for every 1 mL of fetomaternal hemorrhage of Rh-positive packed RBCs or 2 mL of whole blood.[1]

In 1998, this recommendation was reinforced by the American Association of Blood Banks and the American College of Obstetrics and Gynecologists with inclusion of prophylaxis at 28 weeks' gestation.[2] Routine use of Rh IgG prophylaxis resulted in a significant decline in the incidence of RhD alloimmunization,[3] and erythroblastosis fetalis has become rare. The perinatal effects of maternal Rh alloimmunization are now referred to as hemolytic disease of the fetus and newborn, and fetal manifestations of the disease are more appreciated with newer technologies such as cordocentesis and fetal ultrasonography.




Although the Rh antibody was and still is the most common cause of severe hemolytic disease of the newborn, other alloimmune antibodies belonging to Kell (K and k), Duffy (Fya), Kidd (Jka and Jkb), and MNSs (M, N, S, and s) systems do cause severe hemolytic disease of the newborn.[4] The Rh blood group system uses Fisher-Race nomenclature, and the Rh gene complex consists of 3 genetic loci each with 2 major alleles. They code for 5 major antigens denoted by letters, C, c, E, e, and D. Rh blood group antigens are inherited as determined by at least 2 homologous but distinct membrane-associated proteins. Two separate genes (RhCE and RhD), located on the short arm of chromosome 1, encode Rh proteins. Each gene is 10 exons in length, and a 96% homology between these genes is observed.

Production of 2 distinct proteins from the RHCE gene is due to alternative splicing of messenger RNA. Rh gene complex is described by 3 loci, and, therefore, 8 gene complexes are possible. These complexes are as follows (listed in decreasing order of frequency among whites): CDe, cde, CDE, cDe, Cde, cdE, CDE, and CdE. Expression is limited to RBCs, with an increasing density during their maturation, unlike the ABH system, which exists in a wide variety of tissues. Rh antigen is not expressed on RBC progenitors.

Of individuals who are Rh positive, 45% are homozygous (CDe/CDe), and 55% are heterozygous (CDe/cde) for the RhD gene. The Rh-negative phenotype represents absence of D protein on RBCs and most commonly results from deletion of the RHD gene on both chromosomes. However, the RHD gene has significant heterogeneity, and several inherited mutations and rearrangements in its structure can result in a lack of expressions of the RhD phenotype as well.

Important examples of such mutations include the RHD pseudogene and RHD-CE-D hybrid gene. The former leads to a stop codon in RHD gene and results in a lack of transcription product despite all intact exons. It is found in 70% of South African blacks and in 25% of African Americans. The RHD-CE-D (Ccde) gene is also found in 22% of D-negative African Americans. It also results in an Rh positive genotype but a negative phenotype. Most Caucasians who are RhD negative have a complete deletion of RHD gene whereas only 18% of African blacks and 54% of African Americans who are RhD negative have complete deletion of the gene; the rest have above nonfunctional variants of the RHD gene.[5]

Beyond the 5 major antigens, more than 100 antigenic variants of Rh group system have been identified. Individuals with these weak-D phenotypes comprise of 2 populations: first group (90%) that expresses normal but reduced quantities of D antigen on the RBC surface, and most cannot be sensitized to produce anti-D. However, the second group (remaining 10%) known as partial-D (eg, Cw, Du) that express partial D epitopes on RBC surface and can make anti-D and rarely experience fatal hemolytic disease of the newborn. The partial D phenotype results from amino acid sunstitution in the active RhD epitope.[6] Most women with partial-D phenotype are classified as Rh negative on routine testing and are candidates for Rh immune globulin (RhIG). Currently, testing of all Rh-negative women for weak expression of D is not recommended. However, Rh-negative infants born to Rh-negative women should undergo testing to detect the partial-D phenotype so that RhIG can be administeredin theevent ofweak expression.

Frequency of Rh negativity is higher in whites (15%) than in blacks (5%) and Hispanics (8%) and is rare in Eskimos, Native Americans, Japanese, and Asians, especially in Chinese individuals. The paternal heterozygosity determines the likelihood of an Rh-positive child being born to an Rh-negative mother.[3]


The exposure of the Rh-negative mother to Rh-positive red cells occurs as a result of asymptomatic fetomaternal hemorrhage during pregnancy. The Kleihauer-Betke acid elution technique that determines the proportion of fetal RBCs in maternal circulation has shown the incidence of fetomaternal hemorrhage to be 75% of all pregnancies. Incidence and degree of such hemorrhage appears to increase with gestation. Fetomaternal hemorrhage has been documented in 7%, 16%, and 29% of mothers during their first, second and third trimesters, respectively. Risk is also increased in pregnancies complicated by placental abruption, spontaneous or therapeutic abortion, and toxemia, as well as after cesarean delivery and ectopic pregnancy.

Procedures such as amniocentesis, chorionic villus sampling, and cordocentesis also increase the risk of alloimmunization. Because the transplacental hemorrhage is less than 0.1 mL in most pregnancies, most women are sensitized as a result of small, undetectable fetomaternal hemorrhage.

After the initial exposure to a foreign antigen, B-lymphocyte clones that recognize the RBC antigen are established. The maternal immune system initially produces antibodies of the immunoglobulin M (IgM) isotype that do not cross the placenta and later produces antibodies of the IgG isotype that traverse the placental barrier. Predominant antibody subclass appears to be IgG1 in one third of individuals whereas a combination of IgG1 and IgG3 subclasses are found in the remaining individuals.

IgG3 is more efficient in binding to reticuloendothelial cells and causing hemolysis because of its longer hinge region. This is termed the primary response and is dose dependent (documented in 15% of pregnancies with 1 mL of Rh-positive cells in an Rh-negative individual compared with 70% of pregnancies after 250 mL). A repeat exposure to the same antigen rapidly induces the production of IgG. This secondary immune response can be induced with as little as 0.03 mL of Rh-positive RBCs.

The risk of Rh immunization after the delivery of the first child to a nulliparous Rh-negative mother is 16% if the Rh-positive fetus is ABO compatible with its mother, 2% if the fetus is ABO incompatible, and 2-5% after an abortion. The ABO-incompatible RBCs are rapidly destroyed in the maternal circulation, reducing the likelihood of exposure to the immune system. The degree of Rh sensitization of the mother is directly related to the amount of fetomaternal hemorrhage (ie, 3% with < 0.1 mL compared with 22% with >0.1 mL).

After sensitization, maternal anti-D antibodies cross the placenta into fetal circulation and attach to Rh antigen on fetal RBCs, which form rosettes on macrophages in the reticuloendothelial system, especially in the spleen. These antibody-coated RBCs are lysed by lysosomal enzymes released by macrophages and natural killer lymphocytes and are independent of the activation of the complement system.

Reticulocytosis is noted when fetal Hb deficit exceeds 2 gm/dl compared with gestational age norms. Tissue hypoxia develops as fetal anemia becomes severe. When the hemoglobin (Hb) level drops below 8 g/dL, a rise in umbilical arterial lactate occurs. When the Hb level drops below 4g/dL, increased venous lactate is noted. Hydrops fetalis occurs when fetal Hb deficit exceeds 7 g/dL and starts as fetal ascites and evolves into pleural effusions and generalized edema. The various mechanisms responsible for hydrops are hypoalbuminemia secondary to depressed liver function, increased capillary permeability, iron overload secondary to hemolysis, and increased venous pressures due to poor cardiac function.[7]

Prolonged hemolysis leads to severe anemia, which stimulates fetal erythropoiesis in the liver, spleen, bone marrow, and extramedullary sites, such as the skin and placenta. In severe cases, this can lead to displacement and destruction of hepatic parenchyma by erythroid cells, resulting in dysfunction and hypoproteinemia. Destruction of RBCs releases heme that is converted to unconjugated bilirubin. Hyperbilirubinemia becomes apparent only in the delivered newborn because the placenta effectively metabolizes bilirubin. Hemolytic disease of the newborn due to Kell sensitization results in hemolysis and suppression of erythropoiesis because the Kell antigen is expressed on the surface of erythroid progenitors. This leads to severe fetal disease at a lower maternal antibody titer than in Rhesus disease.

Hemolysis associated with ABO incompatibility exclusively occurs in type-O mothers with fetuses who have type A or type B blood, although it has rarely been documented in type-A mothers with type-B infants with a high titer of anti-B IgG. In mothers with type A or type B, naturally occurring antibodies are of the IgM class and do not cross the placenta, whereas 1% of type-O mothers have a high titer of the antibodies of IgG class against both A and B. They cross the placenta and cause hemolysis in fetus.

Hemolysis due to anti-A is more common than hemolysis due to anti-B, and affected neonates usually have positive direct Coombs test results. However, hemolysis due to anti-B IgG can be severe and can lead to exchange transfusion. Because A and B antigens are widely expressed in various tissues besides RBCs, only a small portion of antibodies crossing the placenta are available to bind to fetal RBCs. Recent analysis of IgG subclass in ABO incompatible direct coombs positive neonates showed IgG2 was predominent antibody which is poorly transferred across placenta and less efficient in causing hemolysis while IgG1 was noted in 22% of neonates and as a group had similar rate of hemolysis and severity of hyperbilirubinemia.[8]

In addition, fetal RBCs appear to have less surface expression of A or B antigen, resulting in few reactive sites; hence the low incidence of significant hemolysis in affected neonates. This results in hyperbilirubinemia as a predominant manifestation of incompatibility (rather than anemia), and peripheral blood film frequently reveals a large number of spherocytes and few erythroblasts, unlike what is seen in Rh incompatibility (erythroblastosis fetalis), in which blood film reveals a large number of nucleated RBCs and few spherocytes.[9]




United States

Hemolytic disease of the fetus and newborn affects an estimated 3 in 100,000 to 80 in 100,000 patients annually.[10]

Before the establishment of modern therapy, 1% of all pregnant women developed Rh alloimmunization. Since the advent of routine prophylaxis of at-risk women, incidence of Rh sensitization has declined from 45 cases per 10,000 births to 10.2 cases per 10,000 total births, with less than 10% requiring intrauterine transfusion.[11]  Alloimmunization due to Kell antigen accounts for 10% of severely affected fetuses.

Currently, anti-D is still one of the most common antibodies found in pregnant women, followed by anti-K, anti-c, and anti-E. Of those fetuses who require intrauterine transfusions, 85%, 10%, and 3.5% were due to anti-D, anti-K, and anti-c, respectively.[12] ABO incompatibility frequently occurs during the first pregnancy and is present in approximately 12% of pregnancies, with evidence of fetal sensitization in 3% of live births. Less than 1% of births are associated with significant hemolysis.


Almost 50 different red cell surface antigens have been found to be responsible for hemolytic disease of fetus and newborn. Only 3 antibodies are associated with severe fetal disease: anti-RhD, anti-Rhc, and anti-Kell(K1). Nearly 50% of the affected newborns do not require treatment, have mild anemia and hyperbilirubinemia at birth, and survive and develop normally. Approximately 25% are born near term but become extremely jaundiced without treatment and either die (90%) or become severely affected by kernicterus (10%). The remaining 25% of affected newborns are severely affected in utero and become hydropic; about half of newborns are affected before 34 weeks' gestation, and the other half are affected between 34 weeks' gestation and term.[1]

Before any interventions were available, the perinatal mortality rate was 50%. Wallerstein introduced exchange transfusion in 1945 and reduced the perinatal mortality rate to 25%. Later, Chown suggested the early delivery of those severely affected nonhydropic fetuses by 34 weeks' gestation followed by prompt exchange transfusion helped improve survival. The introduction of intraperitoneal transfusion by William Liley in 1963 and intravascular transfusion (IVT) by Rodeck in 1981 reduced the perinatal morbidity and the mortality rate was further reduced to the current rate of 16%.

Mortality rises to 30% with any degree of fetal hydrops. Most fetuses who are able to reverse fetal hydrops after IVT survive, compared with 25% of those in whom fetal hydrops was severe and persisted despite treatment. The overall rate of neurodevelopmental impairment is 10%, which is comparable to that found in the general population, but hearing loss is increased 5-10 fold over the general population in those infants who require in utero therapy for hemolytic disease of the newborn. The LOTUS study in a Dutch population reported neurodevelopmental outcomes in 281 children with hemolytic disease of the fetus treated with IVT at 8 years, showing normal outcome in 94%, cerebral palsy in 2.1%, severe developmental delay in 3.1%, and bilateral deafness in 1%.[13] Severe hydrops fetalis was the only independent risk factor identified for poor outcome.

No relationship was noted between global developmental scores and the severity of hemolytic disease of the newborn (as evidenced by such factors as the number of intrauterine transfusions [IUTs], the lowest hematocrit [Hct] level, or the presence of hydrops). Normal neurological outcome is noted in more than 90% of infants even if fetal hydrops noted at the time of the first IUT.[14]

Exchange transfusion

A study by Smits-Wintjens et al indicated that exchange transfusion in neonates increases the risk of sepsis, severe thrombocytopenia, leukocytopenia, hypernatremia, and hypocalcemia in neonates with hemolytic disease of the newborn (HDN). The study involved 347 newborns with red cell alloimmune hemolytic disease, including 134 who underwent exchange transfusion and 213 who did not. The incidence of complications in the two groups was, respectively, as follows[15] :

  • Proven sepsis: 8% versus 1%
  • Severe thrombocytopenia: 63% versus 8%
  • Leukocytopenia: 88% versus 23%
  • Hypernatremia: 8% versus 0%
  • Hypocalcemia: 22% versus 1%


Incompatibility involving Rh antigens (anti-D or anti-c) occurs in about 10% of all pregnancies among whites and blacks; in contrast, it is very rare in Asian women.


Fetal sex plays a significant role in the degree of response to maternal antibodies. An apparent 13-fold increase is observed in fetal hydrops in RhD-positive male fetuses compared with female fetuses in similarly sensitized pregnancies.[7]

Contributor Information and Disclosures

Sameer Wagle, MBBS, MD Consulting Staff, Division of Neonatology, Northwest Medical Center of Springdale and Willow Creek Women’s Hospital

Sameer Wagle, MBBS, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association

Disclosure: Nothing to disclose.


Prashant G Deshpande, MD Attending Pediatrician, Department of Pediatrics, Christ Hospital Medical Center and Hope Children's Hospital; Assistant Clinical Professor of Pediatrics, Midwestern University

Prashant G Deshpande, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Telemedicine Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David A Clark, MD Chairman, Professor, Department of Pediatrics, Albany Medical College

David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Pediatric Society, Christian Medical and Dental Associations, Medical Society of the State of New York, New York Academy of Sciences, Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Eastern Society for Pediatric Research, American Medical Association, Connecticut State Medical Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Oussama Itani, MD, FAAP, FACN Clinical Associate Professor of Pediatrics and Human Development, Michigan State University; Medical Director, Department of Neonatology, Borgess Medical Center

Oussama Itani, MD, FAAP, FACN is a member of the following medical societies: American Academy of Pediatrics, American Association for Physician Leadership, American Heart Association, American College of Nutrition

Disclosure: Nothing to disclose.

  1. Bowman JM. Hemolytic disease (erythroblastosis fetalis). Creasy RK, Resnik R. Maternal-fetal medicine. 4th edition. Philadelphia: WB Saunders; 1999. 736-767.

  2. [Guideline] Snyder EL, Lipton KS. Prevention of hemolyic disease of the newborn due to anti-D Prenatal/perinatal testing and Rh immune globulin administration. American Association of Blood Banks Association Bulletin. 1998. 98:1-6.

  3. Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era. Semin Fetal Neonatal Med. 2015 Nov 14. [Medline].

  4. van der Schoot CE, Tax GH, Rijnders RJ, de Haas M, Christiaens GC. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev. 2003 Jan. 17(1):31-44. [Medline].

  5. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood. 2000 Jan 1. 95(1):12-8. [Medline].

  6. Flegel WA. Molecular genetics and clinical applications for RH. Transfus Apher Sci. 2011 Feb. 44(1):81-91. [Medline]. [Full Text].

  7. Moise KJ. Hemolytic disease of the fetus and newborn. Creasy RK, Resnik R. Maternal-fetal Medicine: Principles and Practice. 6th ed. Philadelphia: WB Saunders; 2008. 477-503.

  8. Kaplan M, Na'amad M, Kenan A, et al. Failure to predict hemolysis and hyperbilirubinemia by IgG subclass in blood group A or B infants born to group O mothers. Pediatrics. 2009 Jan. 123(1):e132-7. [Medline].

  9. Luchtman-Jones L, Schwartz AL, Wilson DB. The blood and hematopoietic system. Fanaroff AA, Martin RJ, eds. Neonatal-Perinatal Medicine-Diseases of the Fetus and Infant. 8th ed. St. Louis, Mo: Mosby; 2006. Vol 2: 1287-1356.

  10. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015 Dec 5. 2015 (1):146-51. [Medline].

  11. Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA. 1991 Jun 26. 265(24):3270-4. [Medline].

  12. Eder AF. Update on HDFN: new information on long-standing controversies. Immunohematol. 2006. 22(4):188-95. [Medline].

  13. Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012 Feb. 206(2):141.e1-8. [Medline].

  14. Gruslin-giroux A, Moore TR. Erythroblastosis Fetalis. Fanaroff AA, Martin RJ. Neonatal-Perinatal Medicine. 8th edition. St. Louis, MO: Mosby-year book Inc; 2006. Vol 1: 389-408.

  15. Smits-Wintjens VE, Rath ME, van Zwet EW, et al. Neonatal morbidity after exchange transfusion for red cell alloimmune hemolytic disease. Neonatology. 2013. 103(2):141-7. [Medline].

  16. Moise KJ Jr. Red blood cell alloimmunization in Pregnancy. Seminars in Hematology. 2005. 42:169-178.

  17. Harkness UF, Spinnato JA. Prevention and management of RhD isoimmunization. Clin Perinatol. 2004 Dec. 31(4):721-42, vi. [Medline].

  18. Pirelli KJ, Pietz BC, Johnson ST, Pinder HL, Bellissimo DB. Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D. Prenat Diagn. 2010 Dec. 30(12-13):1207-12. [Medline].

  19. Bianchi DW, Avent ND, Costa JM, van der Schoot CE. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time. Obstet Gynecol. 2005. 106(4):841-4. [Medline].

  20. Rouillac-Le Sciellour C, Puillandre P, Gillot R, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn. 2004. 8(1):23-31. [Medline].

  21. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008 Jul. 112(1):164-76. [Medline].

  22. Liley AW. Liquor amnii analysis in management of pregnancy complicated by rhesus immunization. Am J Obstet Gynecol. 1961. 82:1359-71.

  23. Bowman JM, Pollock JM. Amniotic fluid spectrophotometry and early delivery in the management of erythroblastosis fetalis. Pediatr. 1965 May. 35:815-835. [Medline].

  24. Nicolaides KH, Rodeck CH, Mibashan RS, Kemp JR. Have Liley charts outlived their usefulness?. Am J Obstet Gynecol. 1986 Jul. 155(1):90-4. [Medline].

  25. Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. Am J Obstet Gynecol. 1993 May. 168(5):1370-6. [Medline].

  26. Scott F, Chan FY. Assessment of the clinical usefulness of the "Queenan" chart versus the "Liley" chart in predicting severity of rhesus iso-immuinization. Prenat Diagn. (11) 1998. 18:1143-48. [Medline].

  27. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006 Jul 13. 355(2):156-164. [Medline].

  28. Mentzer, WC, Glader BE. Erythrocyte Disorders in Infancy. Taeusch HW, Ballard RA eds. Avery's Diseases of the Newborn. 8th Edition. Philadelphia, PA: Elsevier Saunders; 2005. 1180-1214.

  29. Brojer E, Husebekk A, Dębska M, et al. Fetal/neonatal alloimmune thrombocytopenia: pathogenesis, diagnostics and prevention. Arch Immunol Ther Exp (Warsz). 2015 Nov 12. [Medline].

  30. Koenig JM. Evaluation and treatment of erythroblastosis fetalis in the neonate. Christensen R, ed. Hematologic Problems of the Neonate. Philadelphia, Pa: WB Saunders; 2000. 185-207.

  31. Wang WH, Xu D, Han YM, Yang ZJ. [Risk factors for early disseminated intravascular coagulation in neonates with sepsis] [Chinese]. Zhongguo Dang Dai Er Ke Za Zhi. 2015 Apr. 17 (4):341-4. [Medline].

  32. Christensen RD, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia. Pediatrics. 2010 Jan. 125(1):120-5. [Medline].

  33. Vidnes J, Finne H. Immunoreactive insulin in amniotic fluid from Rh-immunized women. Biol Neonate. 1977. 31(1-2):1-6. [Medline].

  34. Romano EL, Hughes-Jones NC, Mollison PL. Direct antiglobulin reaction in ABO-haemolytic disease of the newborn. Br Med J. 1973 Mar 3. 1(852):524-6. [Medline].

  35. Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2007 Mar. 92(2):F83-8. [Medline].

  36. Bakkeheim E, Bergerud U, Schmidt-Melbye AC, et al. Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate. Acta Paediatr. 2009 Dec. 98(12):1896-901. [Medline].

  37. Lozar-Krivec J, Bratanic B, Paro-Panjan D. The role of carboxyhemoglobin measured with CO-oximetry in the detection of hemolysis in newborns with ABO alloimmunization. J Matern Fetal Neonatal Med. 2016 Feb. 29 (3):452-6. [Medline].

  38. Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol. 1994 Jul. 171(1):247-52. [Medline].

  39. Bowman J. The management of hemolytic disease in the fetus and newborn. Semin Perinatol. 1997 Feb. 21(1):39-44. [Medline].

  40. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012 Nov. 120(5):1132-9. [Medline].

  41. Zimmerman R, Carpenter RJ Jr, Durig P, Mari G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG. 2002 Jul. 109(7):746-52. [Medline].

  42. ACOG Practice Bulletin No. 75: management of alloimmunization. Obstet Gynecol. 2006 Aug. 108(2):457-64. [Medline].

  43. Opekes D, seward G, Vandenbussche F, et al. Minimally invasive management of rh alloimmunization: Can amniotic fluid delta OD 450 be replaced by Doppler studies? A prospective study multicenter trial. Am J Obstet Gynecol. 2004. 191:S3.

  44. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008 Jul. 112(1):164-76. [Medline].

  45. Scheier M, Hernandez-Andrade E, Fonseca EB, Nicolaides KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol. 2006 Dec. 195(6):1550-6. [Medline].

  46. Detti L, Oz U, Guney I, Ferguson JE, Bahado-Singh RO, Mari G. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. Am J Obstet Gynecol. 2001 Nov. 185(5):1048-51. [Medline].

  47. Schumacher B, Moise KJ. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol. 1996 Jul. 88(1):137-50. [Medline].

  48. Trevett TN, Dorman K, Lamvu G, Moise KJ. Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2005 Feb. 192(2):478-82. [Medline].

  49. Moise KJ. Grand Rounds: Rh disease: It's still a threat. Contemporary Ob/Gyn. 2004/05. 49:34-48.

  50. Voto LS, Mathet ER, Zapaterio JL, Orti J, Lede RL, Margulies M. High-dose gammaglobulin (IVIG) followed by intrauterine transfusions (IUTs): a new alternative for the treatment of severe fetal hemolytic disease. J Perinat Med. 1997. 25(1):85-8. [Medline].

  51. Kriplani A, Singh BM, Mandal K. Fetal intravenous immunoglobulin therapy in Rhesus Hemolytic Disease. Gynecol Obstet Invest. 2007. 63:176-180.

  52. Matsuda H, Yoshida M, Wakamatsu H, Furuya K. Fetal intraperitoneal injection of immunoglobulin diminishes alloimmune hemolysis. J Perinatol. 2011 Apr. 31(4):289-92. [Medline].

  53. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med. 2008 Aug. 13(4):207-14. [Medline].

  54. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003 Jan;88(1):F6-10. 88(1). 2003:F6-10. [Medline].

  55. Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial. Eur J Pediatr. 2011 Apr. 170(4):461-7. [Medline].

  56. Smits-Wintjens VE, Walther FJ, Rath ME, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics. 2011 Apr. 127(4):680-6. [Medline].

  57. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics. 2004 Jan. 113(1 Pt 1):119-23. [Medline].

  58. Madan, A, MacMahon JR, Stevenson DK. Neonatal hyperbilirubinemia. Taeusch HW, Ballard RA, eds. Avery’s Diseases of The Newborn. 8th ed. Philadelphia, Pa: Elsevier Saunders; 2005. 1226-1256.

  59. [Guideline] Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 Jul. 114(1):297-316. [Medline].

  60. Martin CR, Cloherty JP. Neonatal Hyperbilirubinemia. Cloherty JP, Eichenwald EC, Stark AR. Manual of Neonatal Care. 5th Edition. Philadelphia: Lippincott Williams and Wilkins; 2004. 181-212.

  61. Wong RJ, DeSandre GH, Stevenson DK. Neonatal jaundice and liver disease. Fanaroff AA, Martin RJ. Neonatal-Perinatal Medicine: Diseases of the fetus and Infant. 7th edition. St. Louis, MO: Mosby-year book Inc; 2002. Vol 2: 1419-11466.

  62. Peterec SM. Management of neonatal Rh disease. Clin Perinatol. 1995 Sep. 22(3):561-92. [Medline].

  63. Hammerman C, Vreman HJ, Kaplan M, Stevenson DK. Intravenous immune globulin in neonatal immune hemolytic disease: does it reduce hemolysis?. Acta Paediatr. 1996 Nov. 85(11):1351-3. [Medline].

  64. Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial. Eur J Pediatr. 2011 Apr. 170(4):461-7. [Medline].

  65. Figueras-Aloy J, Rodriguez-Miguelez JM, Iriondo-Sanz M, Salvia-Roiges MD, Botet-Mussons F, Carbonell-Estrany X. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics. 2010 Jan. 125(1):139-44. [Medline].

  66. Maisels MJ, Yang H. Tin-mesoporphyrin in the treatment of refractory hyperbilirubinemia due to Rh incompatibility. J Perinatol. 2012 Nov. 32(11):899-900. [Medline].

  67. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec. 12(6):734-40. [Medline].

  68. Ovali F, Samanci N, Dagoglu T. Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res. 1996 May. 39(5):831-4. [Medline].

  69. Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007 Jul. 120(1):27-32. [Medline].

  70. Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics. 2011 Apr. 127(4):680-6. [Medline].

  71. Hudon L, Moise KJ Jr, Hegemier SE, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol. 1998 Oct. 179(4):858-63. [Medline].

  72. Martin JA, Hamilton BE, Sutton PD et al. Births; final data for 2002. Natl Vital Stat Rep. 2002. 52:1-116.

  73. Watchko JF. Common hematologic problems in the newborn nursery. Pediatr Clin North Am. 2015 Apr. 62 (2):509-24. [Medline].

Liley curve. This graph illustrates an example of amniotic fluid spectrophotometric reading of 0.206, which when plotted at 35 weeks' gestation falls into zone 3, indicating severe hemolytic disease.
Modified Liley curve for gestation of less than 24 weeks showing that bilirubin levels in amniotic fluid peak at 23-24 weeks' gestation.
Queenan Curve: Modified Liley curve that shows delta-OD 450 values at 14-40 weeks' gestation.
Slopes for peak systolic velocity in middle cerebral artery (MCA) for normal fetuses (dotted line), mildly anemic fetuses (thin line), and severely anemia fetuses (thick line).
Management of first affected pregnancy.
Management of pregnant women with previously affected fetus.
Table. Comparison of Rh and ABO Incompatibility
Characteristics Rh ABO
Clinical aspects First born 5% 50%
Later pregnancies More severe No increased severity
Stillborn/hydrops Frequent Rare
Severe anemia Frequent Rare
Jaundice Moderate to severe, frequent Mild
Late anemia Frequent Rare
Laboratory findings Direct antibody test Positive Weakly positive
Indirect Coombs test Positive Usually positive
Spherocytosis Rare Frequent
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.